InvestorsHub Logo
icon url

jta1980

01/13/23 7:25 AM

#397865 RE: Investor2014 #397856

Thanks, Investor, I appreciate the response and the thought process used for the answer.
icon url

WolfofMia

01/13/23 8:44 AM

#397884 RE: Investor2014 #397856

You are falling off the deep end. lol

So 3 years to get data then start a P3? or apply for AA? I can't I just can't!!
icon url

end2war

01/13/23 4:13 PM

#398078 RE: Investor2014 #397856

We can also try to answer the question from a logical perspective.

Because a peer reviewed publication can take a long time, it is not entirely logical for Missling to withhold the companies version of the data until it can be peer reviewed.

My previously posted thought was that Missling would provide the data to the FDA, and let them review and comment on it; and, after that, they would likely issue more data and information to the market in an 8K filing. I think they will want to bounce any controversial reading of the data off the FDA to see if the FDA thinks the data can be presented in a pivotal NDA filing before they release it to the Market. I don't think they will wait for the peer reviewed publication for their first release of the full AD study data.

Of course, they also can do a data release in a preliminary 8K filing as soon as possible after it is collected in the spirt that it is material data and MUST be reported to the Market, which is a legal theory that could govern when it is to be released, to wit, as soon as possible.

While his "ish" remarks have been accurately pointed out in the past, this history is just introductory prolog for the future, and not binding. LOL. I submit it is logical to expect a faster presentation in this case.

Also, another thought, is that after AVXL has obtained OL data for 7 months, then it would have a total of 18 months for comparison to the Lecanemab data. It is not uncommon for companies to release part of their OL data as it is developing.

That is another logical point to release the full data because Missling has indicated that his prime argument is likely to be that A-273 is better than an approved drug[Lecanemab]. I expect that logically could happen in the 2nd or 3rd quarter of 2023.